关注
Louise Provencher
Louise Provencher
Centre de recherche du CHU de Québec - Université Laval
在 chudequebec.ca 的电子邮件经过验证
标题
引用次数
引用次数
年份
Adjuvant docetaxel for node-positive breast cancer
M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ...
New England Journal of Medicine 352 (22), 2302-2313, 2005
13472005
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic …
DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ...
Journal of clinical oncology 28 (20), 3239-3247, 2010
10902010
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study
JF Boileau, B Poirier, M Basik, CMB Holloway, L Gaboury, L Sideris, ...
Journal of Clinical Oncology 33 (3), 258-264, 2015
8222015
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M Piccart, GN Hortobagyi, M Campone, KI Pritchard, F Lebrun, Y Ito, ...
Annals of oncology 25 (12), 2357-2362, 2014
6462014
Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review
J Lemieux, E Maunsell, L Provencher
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2008
5212008
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
LS Rosen, DH Gordon, W Dugan Jr, P Major, PD Eisenberg, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2004
4712004
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer
E Grunfeld, JA Julian, G Pond, E Maunsell, D Coyle, A Folkes, AA Joy, ...
Journal of Clinical Oncology 29 (36), 4755-4762, 2011
3732011
NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and …
L Fehrenbacher, RS Cecchini, CE Geyer Jr, P Rastogi, JP Costantino, ...
Journal of Clinical Oncology 38 (5), 444-453, 2020
3072020
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
JR Mackey, M Martin, T Pienkowski, J Rolski, JP Guastalla, A Sami, ...
The Lancet Oncology 14 (1), 72-80, 2013
2662013
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial
S Johnston, S Puhalla, D Wheatley, A Ring, P Barry, C Holcombe, ...
Journal of Clinical Oncology 37 (3), 178-189, 2019
1962019
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2 …
W Eiermann, T Pienkowski, J Crown, S Sadeghi, M Martin, A Chan, ...
Journal of clinical oncology 29 (29), 3877-3884, 2011
1892011
Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
JR Mackey, M Clemons, MA Côté, D Delgado, S Dent, A Paterson, ...
Current Oncology 15 (1), 24, 2008
1872008
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
DW Miles, SL De Haas, LY Dirix, G Romieu, A Chan, X Pivot, P Tomczak, ...
British journal of cancer 108 (5), 1052-1060, 2013
1832013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
SM Swain, G Tang, CE Geyer Jr, P Rastogi, JN Atkins, PP Donnellan, ...
Journal of clinical oncology 31 (26), 3197-3204, 2013
1692013
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer
M Trudeau, F Charbonneau, K Gelmon, K Laing, J Latreille, J Mackey, ...
The lancet oncology 6 (11), 886-898, 2005
1642005
Is clinical breast examination important for breast cancer detection?
L Provencher, JC Hogue, C Desbiens, B Poirier, E Poirier, D Boudreau, ...
Current Oncology 23 (4), 332-339, 2016
1222016
Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab±bevacizumab in patients with HER2-positive, node-positive or high …
DJ Slamon, SM Swain, M Buyse, M Martin, CE Geyer, YH Im, ...
Cancer Research 73 (24_Supplement), S1-03-S1-03, 2013
1172013
Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
GN Hortobagyi, MJ Piccart-Gebhart, HS Rugo, HA Burris, M Campone, ...
Journal of Clinical Oncology 31 (18_suppl), LBA509-LBA509, 2013
1122013
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
J Simard, M Dumont, AM Moisan, V Gaborieau, H Vézina, F Durocher, ...
Journal of medical genetics 44 (2), 107-121, 2007
1112007
Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial
M Al-Akoum, E Maunsell, R Verreault, L Provencher, H Otis, S Dodin
Menopause 16 (2), 307-314, 2009
972009
系统目前无法执行此操作,请稍后再试。
文章 1–20